07 September, 2017
The stock increased 0.79% or $0.25 during the last trading session, reaching $31.87. About 2 shares traded. It has underperformed by 5.47% the S&P500. ABT's SI was 18.47M shares in September as released by FINRA. The company's market cap is $88.82 Billion, and the average volume is 5.68 Million. The SI to Abbott Labs's float is 1.07%. The share last price represents downtick move of -0.43% in value from company's 52-Week high price and shows 36.94% above change in value from its 52-Week low price. About 2 shares traded. Vestor Cap Limited Liability Corporation invested 1.82% of its portfolio in Abbott Laboratories (NYSE:ABT). It has underperformed by 0.80% the S&P500. Banque Pictet & Cie Sa sold 64,431 shares as Abbott Labs (ABT)'s stock declined 3.42%. Therefore 61% are positive. According to these analysts, the Low Revenue Estimate for Abbott Laboratories is 6.67 Billion and the High Revenue Estimate is 6.78 Billion.
While looking at the Stock's Performance, Abbott Laboratories now shows a Weekly Performance of 2.07%, where Monthly Performance is 3.83%, Quarterly performance is 9.94%, 6 Months performance is 12.85% and yearly performance percentage is 21.42%. The stock now has Monthly Volatility of 1.23% and Weekly Volatility of 1.10%. The company was maintained on Tuesday, March 15 by Jefferies. The rating was reinitiated by Credit Suisse with "Outperform" on Monday, August 10. The rating was maintained by RBC Capital Markets with "Outperform" on Thursday, January 26. RBC Capital Markets has "Outperform" rating and $50 target. The rating was maintained by Argus Research with "Buy" on Friday, July 21. Finally, Independent Portfolio Consultants Inc. raised its holdings in Abbott Laboratories by 9.3% during the 1st quarter. Morgan Stanley has "Equal-Weight" rating and $4 target. Cowen and Company reiterated a "buy" rating and issued a $55.00 target price on shares of Abbott Laboratories in a report on Thursday, August 17th.
Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.75, from 1.63 in 2016Q3. It dived, as 83 investors sold ABT shares while 496 reduced holdings. Peavine Capital Ltd Liability holds 0.5% or 21,600 shares. The Lower end of the earnings estimate is $0.64, while the higher end of the earnings estimate is $0.66. Abbott Laboratories's payout ratio is now 149.30%. Da Davidson Comm accumulated 0.15% or 176,124 shares. Check Cap Inc Ca holds 0.28% or 94,351 shares in its portfolio.
Many analysts are providing their Estimated Earnings analysis for Abbott Laboratories and for the current quarter 18 analysts have projected that the stock could give an Average Earnings estimate of $0.65/share. The Return on Equity (ROE) value stands at 4.5%.
Bank Of America Corp De holds 0% of its portfolio in Voxeljet AG (ADR) for 521 shares. Clearbridge Investments Lc stated it has 73,409 shares or 0% of all its holdings. Wealth Architects Ltd Llc has invested 0.17% of its portfolio in Abbott Laboratories (NYSE:ABT). The stock closing price is now trading upward to its 50 day moving average with change of 3.81%, escalated to its 20 day moving average with figure of 3.35% and above its 200 day moving average with value 14.85%.
Since March 31, 2017, it had 0 insider purchases, and 2 selling transactions for $60,722 activity. The insider Contreras Jaime sold 767 shares worth $34,240.
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. ABT generated revenue of $5.58 Billion in the same quarter, one year ago. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 78.6 P/E ratio. The Company's Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Citigroup Inc. assumed coverage on Abbott Laboratories in a report on Thursday, August 17th. Drexel Hamilton has "Buy" rating and $3900 target. Wells Fargo maintained the stock with "Buy" rating in Wednesday, August 5 report. As per Wednesday, August 16, the company rating was maintained by Oppenheimer. First Command Financial Services Inc. now owns 2,787 shares of the healthcare product maker's stock worth $124,000 after buying an additional 257 shares during the period. (NASDAQ:CSCO) earned "Buy" rating by Zacks on Tuesday, August 4. The rating was maintained by Jefferies with "Buy" on Friday, June 16. On Thursday, July 23 the stock rating was maintained by Stifel Nicolaus with "Buy".
Other hedge funds and other institutional investors also recently bought and sold shares of the company. 117 funds opened positions while 651 raised stakes. Russell Investments Group Ltd. now owns 1,737,573 shares of the healthcare product maker's stock valued at $77,173,000 after acquiring an additional 931,847 shares during the period. Blackrock Inc., a New York-based fund reported 25 shares. Washington National Bank accumulated 8,688 shares or 0.08% of the stock. Marietta Prtn stated it has 22,242 shares or 0.3% of all its holdings. Mesirow Fincl Inv reported 14,554 shares.
